Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3079781rdf:typepubmed:Citationlld:pubmed
pubmed-article:3079781lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3079781lifeskim:mentionsumls-concept:C0085612lld:lifeskim
pubmed-article:3079781lifeskim:mentionsumls-concept:C0034414lld:lifeskim
pubmed-article:3079781lifeskim:mentionsumls-concept:C0085251lld:lifeskim
pubmed-article:3079781lifeskim:mentionsumls-concept:C1579762lld:lifeskim
pubmed-article:3079781lifeskim:mentionsumls-concept:C0009491lld:lifeskim
pubmed-article:3079781pubmed:issue1lld:pubmed
pubmed-article:3079781pubmed:dateCreated1986-1-31lld:pubmed
pubmed-article:3079781pubmed:abstractTextThe antiarrhythmic efficacy and safety of oral encainide hydrochloride and quinidine sulfate were compared in a nine center double-blind crossover study in 187 outpatients with benign or potentially lethal ventricular arrhythmias. Patients with at least 30 premature ventricular complexes/h were randomized to receive either encainide, 25 mg four times/day, or quinidine, 200 mg four times/day, for 2 weeks. These doses were continued for another 2 weeks if a 75% or greater reduction in premature ventricular complexes was observed. If this reduction was not seen, encainide was increased to 50 mg four times/day or quinidine to 400 mg four times/day for an additional 2 weeks. Both drugs produced a statistically significant reduction in premature ventricular complex frequency compared with baseline values. Encainide produced a statistically significant greater mean reduction in total premature ventricular complexes than did quinidine during the initial dose phase and after dose adjustment. More patients required dose increases of quinidine (60%) than of encainide (51%). Early discontinuation of treatment resulting in advancement to the next study period occurred in 12 patients taking encainide and 38 patients taking quinidine (p less than 0.05). PR and QRS intervals increased significantly during encainide treatment, as did QTc and JT intervals during quinidine treatment. No adverse reactions resulted from these electrocardiographic changes. Adverse reactions were more common with quinidine than with encainide.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:3079781pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3079781pubmed:languageenglld:pubmed
pubmed-article:3079781pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3079781pubmed:citationSubsetAIMlld:pubmed
pubmed-article:3079781pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3079781pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3079781pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3079781pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3079781pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3079781pubmed:statusMEDLINElld:pubmed
pubmed-article:3079781pubmed:monthJanlld:pubmed
pubmed-article:3079781pubmed:issn0735-1097lld:pubmed
pubmed-article:3079781pubmed:authorpubmed-author:MorganrothJJlld:pubmed
pubmed-article:3079781pubmed:authorpubmed-author:PoolP EPElld:pubmed
pubmed-article:3079781pubmed:authorpubmed-author:LuiE MEMlld:pubmed
pubmed-article:3079781pubmed:authorpubmed-author:SombergJ CJClld:pubmed
pubmed-article:3079781pubmed:authorpubmed-author:LeeI KIKlld:pubmed
pubmed-article:3079781pubmed:authorpubmed-author:SalernoD MDMlld:pubmed
pubmed-article:3079781pubmed:authorpubmed-author:DurkeeJJlld:pubmed
pubmed-article:3079781pubmed:issnTypePrintlld:pubmed
pubmed-article:3079781pubmed:volume7lld:pubmed
pubmed-article:3079781pubmed:ownerNLMlld:pubmed
pubmed-article:3079781pubmed:authorsCompleteYlld:pubmed
pubmed-article:3079781pubmed:pagination9-16lld:pubmed
pubmed-article:3079781pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:meshHeadingpubmed-meshheading:3079781-...lld:pubmed
pubmed-article:3079781pubmed:year1986lld:pubmed
pubmed-article:3079781pubmed:articleTitleComparative study of encainide and quinidine in the treatment of ventricular arrhythmias.lld:pubmed
pubmed-article:3079781pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3079781pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3079781pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3079781pubmed:publicationTypeRandomized Controlled Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3079781lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3079781lld:pubmed